Related Experiment Videos
Testicular histology following chronic gonadotropin-releasing hormone agonist treatment
Abstract:
The histologic appearance of the testes of men exposed to chronic gonadotropin-releasing hormone agonist (GnRH-A) therapy has not been previously documented. Herein, we report on the histologic features of the testes of four patients with disseminated prostatic carcinoma who received at least 1 year of daily treatment with (D-Leu6, des-Gly-NH2(10), proethylamide9)-GnRH (leuprolide, Abbott Laboratories, North Chicago, IL) for their disease, and subsequently underwent bilateral orchiectomy. In marked contrast to the testes from five control patients, the testes of these agonist-treated patients demonstrated absence of spermatogenesis, Leydig cell hypoplasia, and Leydig cell inactivity. These data provide direct histologic evidence that the chronic administration of GnRH agonists may be suitable as a potential male contraceptive.
Insights
Chronic gonadotropin-releasing hormone agonist (GnRH-A) therapy in men caused absence of sperm production and Leydig cell inactivity. These findings suggest GnRH agonists may be effective as a male contraceptive.
Area of Science:
- Reproductive Endocrinology
- Urologic Oncology
- Histopathology
Background:
- The effects of chronic gonadotropin-releasing hormone agonist (GnRH-A) therapy on testicular histology are not well-documented.
- GnRH agonists are used to treat conditions like advanced prostatic carcinoma.
Purpose of the Study:
- To investigate the histologic changes in the testes of men undergoing long-term GnRH-A therapy.
- To evaluate the potential of GnRH agonists as a male contraceptive method.
Main Methods:
- Histologic examination of testicular biopsies from four patients treated with leuprolide (a GnRH agonist) for at least one year.
- Comparison of findings with testicular histology from five control patients.
Main Results:
- Testes from GnRH-A treated patients showed an absence of spermatogenesis (sperm production).
- Leydig cell hypoplasia (reduced number) and inactivity were observed in treated patients.
- Significant contrast in testicular appearance compared to control subjects.
Conclusions:
- Chronic GnRH-A therapy leads to significant histologic alterations in the testes.
- The observed testicular changes, including suppressed spermatogenesis and Leydig cell dysfunction, support the potential use of GnRH agonists as a male contraceptive.